Source of this article and featured image is TechCrunch. Description and key fact are generated by Codevision AI system.
Onepot AI secured $13 million in funding to revolutionize chemical drug development. Founders Daniil Boiko and Andrei Tyrin highlight challenges in molecule synthesis, where traditional methods are slow and costly. Their AI tool, Phil, automates experimental analysis to accelerate compound creation. The startup aims to cut drug discovery timelines by leveraging advanced machine learning and lab data. This innovation addresses global supply chain vulnerabilities and streamlines collaboration between biotech firms and researchers.
Key facts
- Onepot AI raised $13 million in funding, including a seed round led by Fifty Years.
- Founders Daniil Boiko (organic chemistry expert) and Andre, Tyrin (AI specialist) co-developed the platform.
- Phil, an AI chemist, optimizes molecule synthesis by analyzing real-world lab data.
- The startup’s technology reduces compound creation time from months to days, cutting costs significantly.
- Plans include expanding to San Francisco and enhancing compound discovery capabilities.
TAGS:
#AI drug discovery #chemical synthesis #machine learning #pharmaceutical innovation #Startup Funding
